Tirzepatide is the highest-rated GLP-1 in history. 8.5 out of 10 on Drugs.com across 3,066 reviews, beating semaglutide by 1.6 points. In SURMOUNT-5, the only head-to-head trial against semaglutide, tirzepatide produced 20.2 percent weight loss vs 13.7 percent. Real patients on Mounjaro and Zepbound report losing 40 to 100+ pounds over 12 to 18 months. But more than half stopped within a year, and the compounded market just collapsed after the FDA ended the shortage. Here's what the reviews actually say in 2026.
If you're comparing your options, Yucca Health offers compounded tirzepatide at $258 starting and $325 per month on the 6-month plan, with a 4.6 out of 5 Trustpilot rating across 989 reviews. The branded Zepbound vial via LillyDirect now starts at $349 per month. The patient stories and ratings below cover both paths.
🔑 Key Takeaways
- The highest-rated GLP-1 we have data on. 8.5 out of 10 on Drugs.com, 81 percent positive vs 8 percent negative. Both Mounjaro and Zepbound separately outscore semaglutide on every public review platform.
- SURMOUNT-5 settled the question. In a head-to-head 72-week trial published 2024, tirzepatide beat semaglutide 20.2 percent to 13.7 percent on weight loss in patients without diabetes.
- Real patient stories range from 40 to 100+ pounds lost over 12 to 18 months. The reviewers who failed mostly cite severe nausea or constipation that didn't resolve with titration.
- Compounded tirzepatide changed in 2025. The FDA ended the shortage in October 2024 and shut down bulk compounding by March 2025. Yucca, MEDVi, and a handful of others operate under the documented-medical-need exception.
- LillyDirect cut Zepbound vial cash price to $349 to $499 in 2026, depending on dose. That closed most of the gap with compounded providers.
Telehealth Comparison Table
These are the two telehealth providers our readers use most for compounded tirzepatide and branded Zepbound prescriptions.
The Verdict in One Sentence: Tirzepatide Outrates Every GLP-1 We Have Data On
Across every major review platform, tirzepatide produces the highest user satisfaction scores in the GLP-1 class. On Drugs.com, the aggregate is 8.5 out of 10 across 3,066 reviews, with 81 percent of users rating it positively and only 8 percent rating it negatively. That's a wider positive-to-negative split than any other weight-loss drug on the same platform. WebMD numbers run 4.1 to 4.2 out of 5 across both Mounjaro and Zepbound listings, again above semaglutide's 3.6 to 3.8 range. Trustpilot's compounded tirzepatide providers (Yucca at 4.6, MEDVi at 4.4) sit at or above the branded review pages for the same molecule.
The simplest read of that data: tirzepatide works for more people, and the people it doesn't work for tend to give it a fair shake before quitting. It's not a magic drug, but the bar it clears for "would recommend" is genuinely high.
Real Patient Stories: What Tirzepatide Users Actually Lose
Dolly57 on Zepbound, Drugs.com, 10/10 rating
"Started at 7.5mg, four weeks in I'm down 11 pounds without changing anything dramatic about my diet. The food noise is just gone." Drugs.com is one of the few platforms where reviewer handles are stable and easy to verify by date. This review is representative of the early-titration camp, fast results, minimal side effects.
Renee on Mounjaro, WebMD, 5/5
Posting in early 2026: "Down 47 pounds in 9 months on Mounjaro 10mg. My A1C went from 7.8 to 5.9. I'm not pre-diabetic anymore." Mounjaro is FDA-approved for type 2 diabetes, not weight loss, but the off-label weight loss outcomes show up consistently in the reviews.
Anonymous on Zepbound, Drugs.com, 9/10
"80 pounds in 14 months on the 10mg dose. I had stopped weighing myself by month 8 because I didn't want to obsess. My clothes told me what was happening." This is the upper-mid range of what tirzepatide produces in real-world use, consistent with the SURMOUNT-1 trial average of 20.9 percent body weight loss.
Susan on Zepbound, Drugs.com, 10/10
"100 pounds down at 17 months. I was 270 when I started. The thing I notice most is sleep, I sleep so much better." Sleep improvement is a less-discussed but commonly reported benefit, likely tied to reduced inflammation and weight off the chest and airways.
Jamie on compounded tirzepatide via Yucca, Trustpilot
"45 pounds in 8 months. I went with Yucca because branded Zepbound was $1,100 a month before my insurance approved it, and even then the prior authorization fights drove me crazy. Yucca shipped in two days. No fights." This is the dominant theme on Trustpilot for compounded providers, the experience matters as much as the molecule.
Aggregate Ratings Across Every Major Platform
| Platform | Average | Reviews | Notes |
|---|---|---|---|
| Drugs.com (all tirzepatide) | 8.5 / 10 | 3,066 | 81% positive, 8% negative |
| Drugs.com Mounjaro | 8.5 / 10 | ~1,500 | T2D off-label weight loss |
| Drugs.com Zepbound | 8.4 / 10 | ~1,500 | Weight loss labeled use |
| WebMD Mounjaro | 4.1 / 5 | ~400 | T2D users |
| WebMD Zepbound | 4.2 / 5 | ~600 | Weight loss users |
| Trustpilot Yucca compounded | 4.6 / 5 | 989 | 85% five-star |
| Trustpilot MEDVi | 4.4 / 5 | 11,400+ | Largest compounded review base |
| Trustpilot Eden | 3.8 / 5 | ~2,000 | Smaller compounded provider |
Mounjaro vs Zepbound: Same Molecule, Different Use Cases
Both Mounjaro and Zepbound contain tirzepatide, manufactured by Eli Lilly. The differences are entirely about FDA labeling and how that translates to insurance access.
| Mounjaro | Zepbound | |
|---|---|---|
| FDA approval | May 2022, type 2 diabetes | November 2023, chronic weight management |
| Doses | 2.5, 5, 7.5, 10, 12.5, 15 mg weekly | Same doses |
| Pen form | Single-dose KwikPen | Single-dose KwikPen + single-dose vials (2025+) |
| Cash price 2026 (4-pen box) | $987 to $1,112 | $349 (2.5 mg vial) to $699 (15 mg pen) via LillyDirect |
| Best reviews | Diabetes outcomes, A1C drops | Pure weight loss, faster titration approval |
Most patients with type 2 diabetes get Mounjaro because insurance typically covers it for the labeled indication. Patients without diabetes get Zepbound because that's the labeled product for weight loss and Wegovy's competitor. Both are the same active molecule at the same doses.
The SURMOUNT Trials: Why Tirzepatide Beat Semaglutide
Tirzepatide's reviews are strong because the clinical data is strong. The SURMOUNT program produced four landmark obesity trials, and SURMOUNT-5 in 2024 settled the question of whether it's actually better than semaglutide.
SURMOUNT-1 (2022, n=2,539, 72 weeks). Average body weight reduction was 15 percent at the 5 mg dose, 19.5 percent at 10 mg, and 20.9 percent at 15 mg. By comparison, the STEP 1 trial of semaglutide 2.4 mg produced 14.9 percent at 68 weeks. The dose-response curve in SURMOUNT-1 is what convinced clinicians tirzepatide was a different class of drug.
SURMOUNT-3 (2023, n=579, lifestyle intervention then drug). Patients lost 6.9 percent on lifestyle alone over 12 weeks, then continued tirzepatide for 72 more weeks. Total weight loss reached 26.6 percent from baseline. This is the highest weight loss documented in a Phase 3 obesity trial to date.
SURMOUNT-4 (2023, maintenance). After a 36-week lead-in to maximum dose, randomized to continue or switch to placebo. Continuation group kept losing, placebo group regained 14 percent of body weight in a year. The clearer maintenance signal than what STEP 4 showed for semaglutide.
SURMOUNT-5 (2024, n=751, head-to-head vs semaglutide 2.4 mg, 72 weeks). Tirzepatide produced 20.2 percent weight loss vs 13.7 percent on semaglutide. Tirzepatide was statistically superior on every secondary endpoint as well: waist circumference, BMI, body fat. This trial is the reason the conversation around GLP-1s shifted from "Wegovy is best" to "Zepbound is the new standard."
For the complete head-to-head breakdown, see tirzepatide vs semaglutide.
What the Negative Reviews Say
The reviews that rate tirzepatide 1 to 3 out of 10 fall into three categories. The first is severe nausea or vomiting that doesn't subside with titration, the same complaint that comes up across the GLP-1 class. The second is constipation that becomes debilitating, which is more specific to tirzepatide and is partly explained by the dual GIP and GLP-1 mechanism slowing gut motility more than GLP-1 alone. The third is the rebound regain story, patients who lost 50 to 80 pounds, stopped the drug for cost reasons, and regained most of it within 12 months.
The trial data backs this up. The Cleveland Clinic 2025 real-world cohort found 55.9 percent of tirzepatide patients discontinued within one year. The ones who stopped early lost less than half of what those who stayed lost. Tirzepatide is not a "take it for six months and you're done" drug, and the negative reviews are mostly patients who learned that the hard way.
Common side effects in the SURMOUNT-1 trial:
- Nausea: 33 percent
- Diarrhea: 23 percent
- Constipation: 17 percent
- Vomiting: 11 percent
- Discontinuation for adverse events: 6 to 7 percent
For a detailed management protocol, see the tirzepatide side effects guide.
Compounded Tirzepatide Reviews: After the Shortage Ended
The 2026 compounded landscape
The FDA declared the tirzepatide shortage resolved in October 2024. Bulk compounding by 503A pharmacies ended February 18, 2025, and by 503B facilities March 19, 2025. Eli Lilly has filed several lawsuits against telehealth compounders. The narrow legal pathway that remains is documented medical necessity, an allergy to an excipient or a dose form that isn't commercially available. Yucca Health, MEDVi, Henry Meds, and a handful of others continue operating under that exception. Many smaller providers have closed.
| Provider | Trustpilot | 2026 Cash Price (5 mg/mo) | Notable |
|---|---|---|---|
| Yucca Health | 4.6 / 5 (989 reviews) | $258 first / $325 to $385/mo | B12 add, UPS 2-Day, 6-month plan cheapest |
| MEDVi | 4.4 / 5 (11,400+) | $279 first / $399 to $499/mo | Sells both compounded and branded Zepbound |
| Henry Meds | 4.5 / 5 (12,400) | $234 to $349/mo | BBB grade F separately |
| Mochi Health | 4.3 / 5 | ~$208/mo | Uses insurance for office visits |
| Hims/Hers compounded | 3.5 / 5 | $199 to $299/mo | Partially transitioning off compounded |
| Eden | 3.8 / 5 | $299 to $349/mo | Smaller volume |
2026 Cost: Branded Zepbound vs Compounded vs Retail
| Source | Cash price (5 mg/mo) | Form | Insurance needed? |
|---|---|---|---|
| Lilly Savings Card | $25/mo | Pen | Yes, commercial |
| LillyDirect vial (Journey Program) | $399/mo at 5 mg, $449 at 7.5+ | Vial + syringe | No |
| Yucca compounded (6-mo plan) | $325/mo | Injection w/ B12 | No |
| MEDVi compounded refill | $399 to $499/mo | Injection or tablet | No |
| Hims compounded | $199 to $299/mo | Injection | No |
| Costco retail pen | ~$1,050/mo | Pen | No |
| Walmart retail pen | ~$1,090/mo | Pen | No |
For more on the branded vs compounded buying decision, see cheapest tirzepatide in 2026 and the dedicated Yucca Health review.
